Predictive value of ALDH1 and CD44 positivity for radiotherapy response and prognosis in early-stage glottic laryngeal squamous cell carcinoma.

IF 0.7 4区医学 Q4 PATHOLOGY

Polish Journal of Pathology Pub Date : 2022-01-01 DOI:10.5114/pjp.2022.117177

Ozgur Surmelioglu, Kıvılcım Erdogan, Muhammed Dagkiran, Suleyman Ozdemir, Ozgur Tarkan, Aysun Uguz

{"title":"Predictive value of ALDH1 and CD44 positivity for radiotherapy response and prognosis in early-stage glottic laryngeal squamous cell carcinoma.","authors":"Ozgur Surmelioglu, Kıvılcım Erdogan, Muhammed Dagkiran, Suleyman Ozdemir, Ozgur Tarkan, Aysun Uguz","doi":"10.5114/pjp.2022.117177","DOIUrl":null,"url":null,"abstract":"<p><p>To evaluate the predictive value of CD44 and aldehyde dehydrogenase 1 (ALDH1) expression for prognosis and radiotherapy (RT) response in patients with early-stage laryngeal cancer receiving RT. Forty-four patients with early-stage laryngeal cancer diagnosed between 2002 and 2016 were included in the study. The correlation between RT response and pre-treatment immunohistochemical ALDH1 and CD44 staining was evaluated. In addition, survival times were compared between groups. The mean age of the 44 patients was 59.8 ±9.0 (43-81) years and 41 were male. There were 20 patients in the non-recurrent group (all men) and 24 patients in the recurrent group (21 men). Immunohistochemical positivity for ALDH1 was found to be a significant risk factor for RT failure (p = 0.0001), whereas CD44 positivity (p = 0.114) and age group (p = 0.287) were not significant. ALDH1 positivity was identified as a significant predictor of DFS and RT sensitivity, while CD44 positivity did not differ according to RT response.</p>","PeriodicalId":49692,"journal":{"name":"Polish Journal of Pathology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polish Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/pjp.2022.117177","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

To evaluate the predictive value of CD44 and aldehyde dehydrogenase 1 (ALDH1) expression for prognosis and radiotherapy (RT) response in patients with early-stage laryngeal cancer receiving RT. Forty-four patients with early-stage laryngeal cancer diagnosed between 2002 and 2016 were included in the study. The correlation between RT response and pre-treatment immunohistochemical ALDH1 and CD44 staining was evaluated. In addition, survival times were compared between groups. The mean age of the 44 patients was 59.8 ±9.0 (43-81) years and 41 were male. There were 20 patients in the non-recurrent group (all men) and 24 patients in the recurrent group (21 men). Immunohistochemical positivity for ALDH1 was found to be a significant risk factor for RT failure (p = 0.0001), whereas CD44 positivity (p = 0.114) and age group (p = 0.287) were not significant. ALDH1 positivity was identified as a significant predictor of DFS and RT sensitivity, while CD44 positivity did not differ according to RT response.

查看原文本刊更多论文

ALDH1和CD44阳性对早期声门喉癌放疗反应和预后的预测价值。

探讨CD44和醛脱氢酶1 (ALDH1)表达对早期喉癌接受放疗患者预后及放疗(RT)反应的预测价值。本研究纳入2002年至2016年诊断的44例早期喉癌患者。评估RT反应与治疗前免疫组化ALDH1和CD44染色的相关性。并比较各组小鼠的生存时间。44例患者平均年龄59.8±9.0(43 ~ 81)岁，男性41例。非复发组20例(均为男性)，复发组24例(21例男性)。ALDH1免疫组化阳性被发现是RT失败的重要危险因素(p = 0.0001)，而CD44阳性(p = 0.114)和年龄组(p = 0.287)无统计学意义。ALDH1阳性被确定为DFS和RT敏感性的重要预测因子，而CD44阳性没有因RT反应而差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Polish Journal of Pathology PATHOLOGY-

CiteScore

1.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Polish Journal of Pathology is an official magazine of the Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology. For the last 18 years of its presence on the market it has published more than 360 original papers and scientific reports, often quoted in reviewed foreign magazines. A new extended Scientific Board of the quarterly magazine comprises people with recognised achievements in pathomorphology and biology, including molecular biology and cytogenetics, as well as clinical oncology. Polish scientists who are working abroad and are international authorities have also been invited. Apart from presenting scientific reports, the magazine will also play a didactic and training role.